Sugi Predict

Sugi Predict / Compounds / SCHEMBL7186793

SCHEMBL7186793

SCHEMBL7186793

Cc1cc(C)c(C(=O)c2ccccc2[P](=O)C(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c(C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNK3 O14649 2/20 0.37
▸ KCNK9 Q9NPC2 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ HTT P42858 1/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ TAS2R14 Q9NYV8 2/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ ALOX12 P18054 2/20 0.36
▸ TP53 P04637 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ RORC P51449 2/20 0.34
▸ RECQL P46063 1/20 0.33
▸ PTGS1 P23219 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188665 0.96 MEN1 (0.38) KCNK3KCNK9LMNASMN1; SMN2HTT
SCHEMBL7175306 0.91 TAS2R14 (0.39) KCNK3KCNK9LMNATAS2R14CYP3A4
SCHEMBL7187550 0.88 TAS2R14 (0.38) KCNK3KCNK9LMNASMN1; SMN2TAS2R14
SCHEMBL7180933 0.88 TAS2R14 (0.39) KCNK3KCNK9LMNASMN1; SMN2TAS2R14
SCHEMBL7180621 0.88 TAS2R14 (0.38) KCNK3KCNK9LMNATAS2R14CYP3A4
SCHEMBL7730584 0.87 TAS2R14 (0.37) KCNK3KCNK9LMNASMN1; SMN2TAS2R14
SCHEMBL7181426 0.86 TAS2R14 (0.41) KCNK3KCNK9LMNATAS2R14CYP3A4
SCHEMBL7183573 0.86 KMT2A (0.39) KCNK3KCNK9LMNASMN1; SMN2HTT
SCHEMBL7180500 0.86 KMT2A (0.39) KCNK3KCNK9LMNASMN1; SMN2HTT
SCHEMBL7180491 0.85 TAS2R14 (0.39) KCNK3KCNK9LMNATAS2R14CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KCNK3 351/4885KCNK9 352/4885LMNA 3241/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KCNK3 388/4885KCNK9 553/4885LMNA 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.